Presented by ANZGOG, Australia New Zealand Gynaecological Oncology Group, the peak gynaecological oncology group in Australia, representing more than 1400 clinical, allied and laboratory-based members.
To register, please fill in your details below:
This informative philanthropic webinar, features keynote speaker, internationally renowned researcher, and ANZGOG Chair, Professor Clare Scott AM, joined by lived experience advocate, Kristin Young and hosted Karen Livingstone AM, ANZGOG Manager, Advocacy and Development.
Every year in Australia 6,800 women are diagnosed with gynaecological cancer, yet these cancers remain in the shadows with women silently suffering through slow treatment progress and outcomes impeded greatly by lack of investment.
Discoveries over the last ten years have revealed a difficult opponent, however, the advent of targeted therapies has given the first glimmer of real hope for women and their families.
ANZGOG’s research focuses on the five main reproductive organs in gynaecological cancers: ovarian (including fallopian tubes), uterine (including endometrial), cervical, vulval, and vaginal cancers. The overall five-year survival rate for gynaecological cancers is 71%, however, ovarian cancer is considered the deadliest women’s cancer, including breast cancer, with a survival of 49% to five years.
To add to the complexity, 55% of female reproductive cancers are rare – which is the highest proportion of rare classification for solid tumours, but gynaecological cancers remain one of the most under-funded cancer streams.
How can better survival outcomes be achieved for women diagnosed with gynaecological cancers by applying targeted therapies on an individual case-by-case basis, rather than a one-size-fits-all approach? Join us on Wednesday 27 November for our special webinar ‘Why targeted therapies are a game changer for gynaecological cancer’. Presented by ANZGOG.
Meet the speakers
Professor Scott is a medical oncologist at the Peter MacCallum Cancer Centre and the Royal Melbourne and Royal Women’s Hospitals and is Joint Head, Clinical Discovery and Translation and Laboratory Head at the Walter and Eliza Hall Institute of Medical Research and Professor of Gynaecological Cancer at University of Melbourne. She has over 20 years’ experience in treating breast and ovarian cancer and in clinical cancer genetics in Familial Cancer Clinics. Clare has been Principal Investigator for more than ten ovarian cancer clinical trials of targeted therapy leading to high impact publications. In the lab, Clare has developed new ovarian cancer pre-clinical models and is using genomics to study targeted drug combinations to combat drug resistance. Clare has established a rare cancer research program to improve access to targeted treatments for patients diagnosed with a rare cancer. Clare was awarded Member of the Order of Australia (AM) for significant service to gynaecological oncology.
Following an initial diagnosis in 2011, Kristin is what is known in ovarian cancer circles as a ‘super responder’. Kristin knows firsthand the importance of research, being one of the initial patients enrolled to a clinical trial in Australia using PARP Inhibitors – a treatment now used widely in familial ovarian cancer. Through women like Kristin participating in the trial, investigators were able to demonstrate that cancer cells can be stopped from repairing themselves in the DNA process. Kristin brings a unique and meaningful point of view to this conversation. Kristin also actively volunteers for ANZGOG’s Survivors Teaching Students® program – a ground-breaking body of work that has brought people with a lived experience of gynaecological cancer into the classrooms of medical students since 2016. 
Karen has been involved with ANZGOG since 2008, including a decade as a Board Director. She is the Advocacy and Development Manager for ANZGOG.
In 2001 Karen Livingstone AM, along with a small, dedicated group founded the ovarian cancer consumer movement in Australia to ensure no woman would travel alone after a diagnosis. Since that time, Karen has been pushing for increased awareness and funding for research to improve survival for women. There are personal motivations for her to help drive research. Karen and her family have a BRCA mutation which led to the passing of her mother and aunt to ovarian cancer.
In a huge honour, Karen was named a Finalist in the Victoria Australian of the Year 2018 and in 2019 was awarded a Member of the Order of Australia for significant service to community health as an advocate for ovarian cancer research.
Please join us by registering here:
